Were Kevin McLaughlin’s Vericel (VCEL) share sales under a 10b5-1 plan?

Yes. The filing states the Vericel share sales were executed under an automatic Rule 10b5-1 trading plan adopted by Kevin McLaughlin on March 11, 2024. Such plans pre-schedule trades to help manage insider trading compliance.

Vericel director exercises options, sells 7,000 shares

Q: What insider transactions did Vericel (VCEL) director Kevin McLaughlin report?

Kevin McLaughlin reported exercising 7,000 stock options at $2.63 per share and selling 7,000 Vericel common shares at $34.66 per share. These transactions occurred on February 11, 2026 and changed his direct share and option holdings.

Q: What Vericel (VCEL) stock options does Kevin McLaughlin still hold?

Following the reported exercise, Kevin McLaughlin holds 3,500 stock options with a $2.63 exercise price expiring on May 3, 2027. These options are part of an original grant for 17,500 shares made on May 3, 2017.

Q: What was the origin of Kevin McLaughlin’s exercised Vericel (VCEL) options?

The exercised options came from a grant made on May 3, 2017 covering 17,500 shares. They became exercisable in equal monthly installments over one year, contingent on continued service to Vericel, according to the Form 4 footnotes.

Vericel director Kevin F. McLaughlin reported an option exercise and share sale.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vericel director Kevin F. McLaughlin reported an option exercise and share sale. On February 11, 2026, he exercised 7,000 stock options with a $2.63 exercise price, receiving 7,000 shares of common stock and bringing his direct holdings to 22,100 shares.

That same day, he sold 7,000 common shares in an open-market transaction at $34.66 per share under a pre-established Rule 10b5-1 trading plan, leaving him with 15,100 directly owned shares. Following the exercise, he also held 3,500 stock options at a $2.63 exercise price expiring on May 3, 2027, from an original grant covering 17,500 shares.

Insider Trade Summary

Exercise and Sale: 7,000 shares ($224K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider MCLAUGHLIN KEVIN F

Role Director

Sold 7,000 shs ($243K)

Approx. gross sale proceeds $243K

Approx. exercise cost $18K

Approx. pre-tax spread $224K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,000	$0.00	$0.00
Exercise	Common Stock	7,000	$2.63	$18K
Sale	Common Stock	7,000	$34.66	$243K

Holdings After Transaction: Stock Option (Right to Buy) — 3,500 contracts (Direct); Common Stock — 15,100 shares (Direct)

Footnotes (2)

F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024.
F2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Vericel (VCEL) director Kevin McLaughlin report?

Kevin McLaughlin reported exercising 7,000 stock options at $2.63 per share and selling 7,000 Vericel common shares at $34.66 per share. These transactions occurred on February 11, 2026 and changed his direct share and option holdings.

How many Vericel (VCEL) shares does Kevin McLaughlin own after this Form 4?

After the reported transactions, Kevin McLaughlin directly owns 15,100 shares of Vericel common stock. This reflects his exercise of 7,000 options followed by the sale of 7,000 shares on February 11, 2026, as disclosed in the Form 4 filing.

At what prices did Kevin McLaughlin exercise and sell Vericel (VCEL) shares?

Kevin McLaughlin exercised Vericel stock options at an exercise price of $2.63 per share and sold 7,000 common shares at $34.66 per share. Both the option exercise and share sale occurred on February 11, 2026.

What Vericel (VCEL) stock options does Kevin McLaughlin still hold?

Following the reported exercise, Kevin McLaughlin holds 3,500 stock options with a $2.63 exercise price expiring on May 3, 2027. These options are part of an original grant for 17,500 shares made on May 3, 2017.

What was the origin of Kevin McLaughlin’s exercised Vericel (VCEL) options?

The exercised options came from a grant made on May 3, 2017 covering 17,500 shares. They became exercisable in equal monthly installments over one year, contingent on continued service to Vericel, according to the Form 4 footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/13/2026 - 04:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCLAUGHLIN KEVIN F

(Last)

(First)

(Middle)

C/O VERICEL CORPORATION

64 SIDNEY STREET

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vericel Corp [ VCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/11/2026		M		7,000	A	$2.63	22,100	D
Common Stock	02/11/2026		S		7,000	D⁽¹⁾	$34.66	15,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.63	02/11/2026		M		7,000		⁽²⁾	05/03/2027	Common Stock	7,000	$0	3,500	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024.

2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

	/s/ Sean Flynn, as Attorney-in-Fact for Kevin McLaughlin	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR